RxDoctor Payments Data

Cory Frey, APRN

Family · Reno, NVNPI 1326617994

Payments from drug & device makers

$2,141in general payments, 2019–2025

Across 22 payments — averaging $97.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$247
  • Amgen$236
  • AstraZeneca$228
  • Corcept Therapeutics$219
  • Bridgebio Pharma, Inc.$138
  • Teva Pharmaceuticals USA, Inc.$138
  • plus $935 from 10 others

What the payments were for

  • Food & beverage$2,141100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,141 in reported general payments places this provider in the 80th percentile of 1,501 family providers in Nevada.

See all family providers in Nevada

Medicare billing

Part B allowed, 2024
$74,437
Medicare patients
336
Services billed
1,126

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide60$64,037
JardianceEmpagliflozin48$47,996
OzempicSemaglutide19$26,071
EliquisApixaban13$22,164
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$16,949
Advair HfaFluticasone Propion/Salmeterol12$5,651
Atorvastatin Calcium302$5,467
Levothyroxine Sodium340$5,403
Telmisartan82$4,695
Fluticasone-SalmeterolFluticasone Propion/Salmeterol31$4,397
Rosuvastatin Calcium188$4,293
Wixela InhubFluticasone Propion/Salmeterol22$3,564
Losartan Potassium142$2,609
Omeprazole154$2,444
Armour ThyroidThyroid,pork15$2,129

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$108$64,03760 claims
AbbVieArmour Thyroid, Synthroid$86$3,95537 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,501 family providers in Nevada.

Other family in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →